Contact Us
  • Home
  • About
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Research
  • The Technology
    • Cole Relaxation Frequency
    • Platform Technology
    • Predictive Technology
    • MarginScan™
    • nsCanary™
    • Targeted Drug Delivery
    • Electrical Mammogram
  • Clinical Results
  • Press
  • Contact Us
  • Home
  • About
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Research
  • The Technology
    • Cole Relaxation Frequency
    • Platform Technology
    • Predictive Technology
    • MarginScan™
    • nsCanary™
    • Targeted Drug Delivery
    • Electrical Mammogram
  • Clinical Results
  • Press
  • Contact Us
  • Home
  • About
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Research
  • The Technology
    • Cole Relaxation Frequency
    • Platform Technology
    • Predictive Technology
    • MarginScan™
    • nsCanary™
    • Targeted Drug Delivery
    • Electrical Mammogram
  • Clinical Results
  • Press
  • Contact Us

About

Recent Posts

  • NovaScan Awarded $3.7 Million CPRIT Grant to Advance MarginScan™ for Breast Cancer Surgery
  • Study Involving NovaScan’s Groundbreaking MarginScan™ Intraoperative Cancer Device Selected for Presentation at 2025 AAD Innovation Academy
  • Clinical Results with NovaScan MarginScan™ Device to be Presented at Wisconsin Dermatology Society Meeting
  • NovaScan Announces a New Pancreatic Trial at the University of Illinois Medical Center
  • NovaScan Announces the Appointment of Two Luminary Advisors

Recent Comments

No comments to show.

Easy to use, ex vivo and in vivo cancer detection that provides instantaneous, highly accurate results, without capital equipment.

 

Address

NovaScan, Inc.
1623 W Fulton St.
Chicago, IL 60612

Contact

Email: cdavis@novascanllc.com
Phone: 312-952-7701

© 2023 NovaScan LLC. All Rights Reserved